(News Bulletin 247) – Stifel reaffirms its ‘buy’ recommendation and its price target of 108 euros on bioMérieux, after a publication deemed ‘mixed’ by the in vitro diagnostics group for its first half, last Friday.
While sales came out in line with the consensus, the broker notes that current operating profit was lower than expected, and that the objectives maintained for 2023 now imply rather weak growth in the second half.
“The band has a lot to look forward to in the coming months (Spotfire, Vidas kube and Vitek instruments), so we think there’s room for positive surprises,” Stifel said nonetheless.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
